McKesson recalls Gemcitabine Injection
- Recalling company
- McKesson
- Product
- Gemcitabine Injection, 1 g per 26.3 mL (38 mg/mL), 26.3 mL Single-Dose Vial, For Intravenous Infusion ONLY, Rx only, Manufactured by: THYMOORGAN PHARMAZIE GmbH, Schiffgraben 23, 38690 Goslar, Germany; Distributed by: Hikma, Berkeley Heights, NJ 07922. NDC: 0143-9341-01
- Reason
- Temperature Abuse: Product was stored incorrectly in a controlled room temperature environment instead of a refrigerated environment.
- Classification
- Class II – may cause temporary or medically reversible health consequences
- Recall date
- Jun 10, 2026
- Reported
- Jul 8, 2026
- Distribution
- Nationwide within the United States
- Status
- Ongoing
- Quantity
- 74 units
- Lot / codes
- Lot #: CB0046, Exp. Date 06/2027
- Company location
- Irving, TX
- Recall type
- Voluntary: Firm initiated
- Recall number
- D-0714-2026
- Agency
- U.S. Food and Drug Administration (FDA)
View official FDA notice ↗ Search recall number D-0714-2026 in the FDA Enforcement Report. Also see FDA recall press releases.
If you use this product, check the lot, NDC or model number against the official notice and follow its instructions. Do not stop a prescribed medicine or remove a medical device without talking to your doctor or pharmacist. Report problems to FDA MedWatch. FoodRecallNow summarizes public FDA data and is not medical advice.